Aminologics Co.Ltd
Aminologics Co.,Ltd., a specialty amino acid provider, develops a range of amino-acid-based raw materials for pharmaceutical and fine chemical industries in South Korea. Its products include D-phenylalanine, D-alanine, D-cysteine, D-serine, D-allo-isoleucine, D-allo-threonine, S-beta-phenylalanine, 3-(2-napthyl)-D-alanine, 4-chloro-D-phenylalanine, 3-(2-napthyl)-L-alanine, R-beta-phenylalanine, D… Read more
Aminologics Co.Ltd (074430) - Total Assets
Latest total assets as of September 2025: ₩83.03 Billion KRW
Based on the latest financial reports, Aminologics Co.Ltd (074430) holds total assets worth ₩83.03 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Aminologics Co.Ltd - Total Assets Trend (2008–2024)
This chart illustrates how Aminologics Co.Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Aminologics Co.Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Aminologics Co.Ltd's total assets of ₩83.03 Billion consist of 81.9% current assets and 18.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩18.88 Billion | 0.0% |
| Accounts Receivable | ₩4.61 Billion | 8.1% |
| Inventory | ₩6.08 Billion | 10.7% |
| Property, Plant & Equipment | ₩3.09 Billion | 5.4% |
| Intangible Assets | ₩3.05 Billion | 5.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Aminologics Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aminologics Co.Ltd's current assets represent 81.9% of total assets in 2024, an increase from 0.0% in 2008.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 23.6% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 10.0% in 2008.
- Asset Diversification: The largest asset category is cash and equivalents at 0.0% of total assets.
Aminologics Co.Ltd Competitors by Total Assets
Key competitors of Aminologics Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AGP Ltd
KAR:AGP
|
Pakistan | PKRs28.27 Billion |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩529.96 Billion |
|
DongKoo Bio&Pharma Co. Ltd
KQ:006620
|
Korea | ₩269.00 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Sam-A Pharm. Co. Ltd
KQ:009300
|
Korea | ₩246.13 Billion |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040
|
Korea | ₩291.47 Billion |
|
WooGene B&G Co. Ltd
KQ:018620
|
Korea | ₩117.10 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩154.14 Billion |
Aminologics Co.Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Aminologics Co.Ltd generates 0.30x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Aminologics Co.Ltd is currently not profitable relative to its asset base.
Aminologics Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.90 | 16.39 | 5.84 |
| Quick Ratio | 2.67 | 14.15 | 5.00 |
| Cash Ratio | 0.00 | 6.74 | 0.00 |
| Working Capital | ₩49.92 Billion | ₩ 41.84 Billion | ₩ 29.28 Billion |
Aminologics Co.Ltd - Advanced Valuation Insights
This section examines the relationship between Aminologics Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.68 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -1.5% |
| Total Assets | ₩56.79 Billion |
| Market Capitalization | $58.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aminologics Co.Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Aminologics Co.Ltd's assets decreased by 1.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Aminologics Co.Ltd (2008–2024)
The table below shows the annual total assets of Aminologics Co.Ltd from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩56.79 Billion | -1.52% |
| 2023-12-31 | ₩57.67 Billion | +3.75% |
| 2022-12-31 | ₩55.58 Billion | -14.81% |
| 2021-12-31 | ₩65.24 Billion | +8.51% |
| 2020-12-31 | ₩60.13 Billion | +4.08% |
| 2019-12-31 | ₩57.77 Billion | +1.61% |
| 2018-12-31 | ₩56.86 Billion | +15.17% |
| 2017-12-31 | ₩49.37 Billion | +0.70% |
| 2016-12-31 | ₩49.03 Billion | -10.91% |
| 2015-12-31 | ₩55.03 Billion | +42.44% |
| 2014-12-31 | ₩38.63 Billion | -19.86% |
| 2013-12-31 | ₩48.20 Billion | -8.53% |
| 2012-12-31 | ₩52.70 Billion | -37.39% |
| 2011-12-31 | ₩84.17 Billion | +43.01% |
| 2010-12-31 | ₩58.86 Billion | -11.11% |
| 2008-12-31 | ₩66.21 Billion | -- |